Not reviewed by FDA for safety, efficacy, or quality
Trial registration UMIN000011118 (date of registration: July 4, 2013)
(2021) 46:E35868
This is why clinicians use intravenous L-carnitine for documented deficiency rather than relying on pills
Ongoing research continues to evaluate the role of these agents in populations without diabetes, particularly in the context of obesity and primary cardiovascular prevention, suggesting that their therapeutic reach may expand further in the coming years
However, as suggested by a previous MR study [23], uric acid is downstream of l-carnitine, i.e., a mediator, so we did not exclude it as an invalid genetic instrument